September 2025
1. SANTIAGO LR, Ladoukakis E, Scibior-Bentkowska D, Nedjai B, et al
   Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer.
   Int J Cancer. 2025 Sep 16. doi: 10.1002/ijc.70163.
   

   >> Share

   
   
2. CHOPRA R, Li H, Xie W, Lam DHT, et al
   Arrhythmic expression signatures of circadian clock-associated transcription factors and chronic circadian disruption contribute to advanced prostate cancer growth.
   Int J Cancer. 2025 Sep 15. doi: 10.1002/ijc.70149.
   

   >> Share

   
   
3. LIN E, Garmo H, Beckmann K, Bratt O, et al
   Prostate cancer characteristics in fathers and risk of early onset high-risk prostate cancer in sons.
   Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70133.
   

   >> Share

   
   
4. BRITO-ROCHA T, Constancio V, Leite-Silva P, Carvalho-Maia C, et al
   Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test.
   Int J Cancer. 2025;157:1006-1019.
   

   >> Share

   
   August 2025
5. HAN Y, Li C, Sun J, Wu G, et al
   Comments on "CTHRC1 promotes bone metastasis in prostate cancer".
   Int J Cancer. 2025 Aug 8. doi: 10.1002/ijc.70081.
   

   >> Share

   
   July 2025
6. OKWOR UE, Raitanen J, Talala K, Tammela TLJ, et al
   Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial.
   Int J Cancer. 2025 Jul 17. doi: 10.1002/ijc.70026.
   

   >> Share

   
   
7. MUCHADEYI MT, Hao S, Hernandez-Villafuerte K, Khan SA, et al
   Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study.
   Int J Cancer. 2025 Jul 16. doi: 10.1002/ijc.35513.
   

   >> Share

   
   June 2025
8. STITZ R, Stoiber F, Silye R, Rebhan E, et al
   Clinical impact of real-time androgen receptor alteration monitoring on metastatic castration-resistant prostate cancer treatment in real-world settings.
   Int J Cancer. 2025 Jun 25. doi: 10.1002/ijc.70019.
   

   >> Share

   
   
9. SAWADA Y, Kikugawa T, Onishi T, Arai O, et al
   CTHRC1 promotes bone metastasis in prostate cancer.
   Int J Cancer. 2025 Jun 21. doi: 10.1002/ijc.70012.
   

   >> Share

   
   December 2024
10. SIECH C, de Angelis M, Jannello LMI, Di Bello F, et al
    Life expectancy in rare histological prostate cancer subtypes.
    Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35323.
    

    >> Share

    
    
11. MCGRATH CB, Shreves AH, Shanahan MR, Guard HE, et al
    Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors.
    Int J Cancer. 2024 Dec 11. doi: 10.1002/ijc.35279.
    

    >> Share

    
    October 2024
12. GRENVILLE ZS, Noor U, Rinaldi S, Gunter MJ, et al
    Perturbations in the blood metabolome up to a decade before prostate cancer diagnosis in 4387 matched case-control sets from the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2024 Oct 8. doi: 10.1002/ijc.35208.
    

    >> Share

    
    September 2024
13. MOGHUL M, Tran A, Croft F, Kinsella N, et al
    The Man Van: A pilot study of using mobile targeted case-finding to address health inequalities in prostate cancer.
    Int J Cancer. 2024 Sep 4. doi: 10.1002/ijc.35169.
    

    >> Share

    
    July 2024
14. BUCK SAJ, Talebi Z, Drabison T, Jin Y, et al
    Darolutamide does not interfere with OATP-mediated uptake of docetaxel.
    Int J Cancer. 2024;155:314-323.
    

    >> Share

    
    June 2024
15. HUANG CY, Huang CP, Huang YY, Huang SK, et al
    Real-world safety and effectiveness of radium-223 in patients with metastatic castration-resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study.
    Int J Cancer. 2024 Jun 26. doi: 10.1002/ijc.35040.
    

    >> Share

    
    
16. SEE AW, Conway P, Frydenberg M, Haxhimolla H, et al
    Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial.
    Int J Cancer. 2024 Jun 19. doi: 10.1002/ijc.35052.
    

    >> Share

    
    April 2024
17. LUO Y, Yu J, Lin Z, Wang X, et al
    Metabolic characterization of sphere-derived prostate cancer stem cells reveals aberrant urea cycle in stemness maintenance.
    Int J Cancer. 2024 Apr 22. doi: 10.1002/ijc.34967.
    

    >> Share

    
    
18. WEISS S, Lamy P, Rusan M, Norgaard M, et al
    Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
    Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34949.
    

    >> Share

    
    March 2024
19. STROMBERG U, Berglund A, Carlsson S, Thellenberg Karlsson C, et al
    Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden.
    Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34932.
    

    >> Share

    
    
20. LEHTO TK, Pylvalainen J, Sandeman K, Kenttamies A, et al
    Histomic and transcriptomic features of MRI-visible and invisible clinically significant prostate cancers are associated with prognosis.
    Int J Cancer. 2024;154:926-939.
    

    >> Share

    
    
21. ZHANG Y, Stopsack KH, Song M, Mucci LA, et al
    Healthy dietary patterns and risk of prostate cancer in men at high genetic risk.
    Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34898.
    

    >> Share

    
    February 2024
22. CARUANA M, Gulati R, Etzioni R, Barratt A, et al
    Benefits and harms of prostate specific antigen testing according to Australian guidelines.
    Int J Cancer. 2024;154:648-658.
    

    >> Share

    
    January 2024
23. SCHUURMAN MS, Lemmens VEPP, Portielje JEA, van der Aa MA, et al
    The cancer burden in the oldest-old: Increasing numbers and disparities-A nationwide study in the Netherlands, 1990 to 2019.
    Int J Cancer. 2024;154:261-272.
    

    >> Share

    
    
24. ZAHED H, Feng X, Sheikh M, Bray F, et al
    Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study.
    Int J Cancer. 2024;154:28-40.
    

    >> Share

    
    November 2023
25. RANGANATHAN S, Dee EC, Debnath N, Patel TA, et al
    Access and barriers to genomic classifiers for breast cancer and prostate cancer in India.
    Int J Cancer. 2023 Nov 14. doi: 10.1002/ijc.34784.
    

    >> Share

    
    
26. NG HUNG SHIN B, Tan S, Rhee H, Chung E, et al
    Impact of the COVID-19 pandemic on delivery of prostate cancer care in Australia: An interrupted time series analysis.
    Int J Cancer. 2023 Nov 3. doi: 10.1002/ijc.34759.
    

    >> Share

    
    
27. FREI K, Schecher S, Daher T, Horner N, et al
    Inhibition of the Cyclin K-CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer.
    Int J Cancer. 2023 Nov 2. doi: 10.1002/ijc.34778.
    

    >> Share

    
    October 2023
28. ALMURADOVA E, Seyyar M, Arak H, Tamer F, et al
    The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.
    Int J Cancer. 2023 Oct 11. doi: 10.1002/ijc.34749.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share